The LIBERTAS study: Advancing health equity for sexual and gender minorities in prostate cancer research

The LIBERTAS study by Johnson & Johnson is pioneering research that aims to advance health equity for sexual and gender minorities in prostate cancer research. It is the company's first oncology program to intentionally include transgender patients, focusing on improving care and treatment options for metastatic prostate cancer. The study evaluates whether patients can de-escalate cancer therapy to enhance quality of life without increasing the risk of poor outcomes. This inclusive approach seeks to gather crucial data on prostate cancer outcomes for nonbinary, transgender, and other LGBTQIA+ individuals.

For more details, you can read the full article here.